An AstraZeneca, Bristol Myers Squibb merger could create a cancer-drug giant, but analysts call it ‘odd’
MarketWatchPaywall
Read Full Article at MarketWatch →Ad Slot — In-Article (728x90)
AstraZeneca shares were slumping while Bristol-Myers Squibb’s stock was jumping on Monday on reported deal talks. But the big question is why these two pharmaceutical giants would want to come together in the first place.
This is a summary. For the full story, read the original article at MarketWatch.
Original source: MarketWatch